CHR-3996

Research use only, not for human use.

CHR-3996 (Nanatinostat, VRx-3996, CHR3996, Tractinostat) is a potent, class I-selective, orally active HDAC inhibitor with IC50 of 3-7 nM for HDAC1/2/3.

CHR-3996 (Nanatinostat, VRx-3996, CHR3996, Tractinostat) is a potent, class I-selective, orally active HDAC inhibitor with IC50 of 3-7 nM for HDAC1/2/3; displays little to no activity against HDAC5 and HDAC6 (IC50=200-2000 nM); demonstrates growth inhibition of HCT116 cells with GI50 of 72 nM, shows efficacy in human tumor xenograft and exhibits good activity in combination with other anticancer agents.Blood Cancer Phase 2 Clinical

Nanatinostat;CHR3996;VRx-3996;Tractinostat

Cell Cycle/DNA Damage

HDAC

HDAC

Cancer

Blood cancer

1256448-47-1

394.41

C20H19FN6O2

>98% (HPLC)

——

O=C(C1=CN=C(N2C[C@]3([H])[C@@H](NCC4=NC5=CC=C(F)C=C5C=C4)[C@]3([H])C2)N=C1)NO

2-[(1R,5S,6s)-6-{[(6-fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]-N-hydroxypyrimidine-5-carboxamide

(-20℃)

With Ice Pack

≥ 2 years